Lancashire and South Cumbria
Formulary
Formulary
10 Musculoskeletal and joint diseases
10-01 Drugs used in rheumatic diseases and gout
Links
Biosimilars policy statement- Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA DSU April 2019: Belimumab (Benlysta): increased risk of serious psychiatric events seen in clinical trials
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA752:Belimumab for treating active autoantibody-positive systemic lupus erythematosus
- NICE TA806: Belimumab for treating lupus nephritis (terminated appraisal)